AbCellera Biologics Inc (OQ:ABCL)

Business Focus: Biotechnology & Medical Research

May 29, 2023 04:05 pm ET
AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, California on Tuesday, June 13, 2023, at 1:20 p.m. Pacific Time (4:20 p.m. Eastern Time).
May 24, 2023 01:10 pm ET
AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients
AbCellera (Nasdaq: ABCL) today announced a CA$701 million co-investment with the Governments of Canada and British Columbia to build new capabilities and infrastructure to develop innovative antibody-based medicines and strengthen Canada’s leadership in clinical research, manufacturing, and drug development. Over the next eight years, AbCellera plans to inves
May 04, 2023 04:05 pm ET
AbCellera Reports Q1 2023 Business Results
AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2023. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
Apr 17, 2023 09:10 am ET
AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023
AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) platform in two poster presentations at the American Society for Cancer Research (AACR) Annual Meeting 2023, which is being held at the Orange County Convention Center in Orlando, Florida, from April 14 to 19, 2023. AbCellera debuted its TCE platform at
Apr 11, 2023 04:05 pm ET
AbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 2023 Bloom Burton & Co. Healthcare Investor Conference in Toronto on Tuesday, April 25, 2023, at 6:30 a.m. Pacific Time (9:30 a.m. Eastern Time).
Apr 06, 2023 04:05 pm ET
AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023
AbCellera (Nasdaq: ABCL) will announce its first quarter 2023 financial results on Thursday, May 4, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
Mar 22, 2023 09:00 am ET
AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease
AbCellera (Nasdaq: ABCL) and RQ Bio announced today that they have entered into a strategic collaboration to identi
Mar 14, 2023 04:30 pm ET
AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023
AbCellera (Nasdaq: ABCL) today announced two upcoming poster presentations on its T-cell engager platform at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held at the Orange County Convention Center in Orlando, Florida, from April 14 to 19.
Feb 23, 2023 04:05 pm ET
AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023
AbCellera (Nasdaq: ABCL) today announced that it will present at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023, at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).
Feb 21, 2023 04:05 pm ET
AbCellera Reports Full Year 2022 Business Results
AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2022. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
Feb 01, 2023 04:05 pm ET
AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023
AbCellera (Nasdaq: ABCL) today announced that it will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023, at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time).
Jan 24, 2023 04:05 pm ET
AbCellera to Report Full Year 2022 Financial Results on February 21, 2023
AbCellera (Nasdaq: ABCL) will announce its full year 2022 financial results on Tuesday, February 21, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
Jan 19, 2023 07:00 pm ET
AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent
AbCellera (Nasdaq: ABCL) today announced that the United States Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has ruled in favor of AbCellera in an Inter Partes Review (IPR) filed by Berkeley Lights, Inc. (Berkeley Lights) that challenged AbCellera’s U.S. Patent No. 10,087,408 (the ‘408 Patent). AbCellera’s ‘408 Patent is directed
Jan 04, 2023 04:05 pm ET
AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time).
Dec 15, 2022 07:00 am ET
AbCellera and AbbVie Partner to Advance New Antibody Therapies
AbCellera (Nasdaq: ABCL) announced today that it has entered into a multi-year, multi-target strategic collaboration with AbbVie
Dec 01, 2022 07:00 am ET
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases
AbCellera (Nasdaq: ABCL) and Rallybio Corporation (Nasdaq: RLYB) announced today that they have entered into a s
Dec 01, 2022 04:00 am ET
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases
AbCellera (Nasdaq: ABCL) and Rallybio Corporation (Nasdaq: RLYB) announced today that they have entered into a s
Nov 10, 2022 08:05 am ET
AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022
AbCellera (Nasdaq: ABCL) today announced the release of new data on its T-cell engager (TCE) platform at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held virtually and at the Boston Convention & Exhibition Center from November 8 to 12, 2022. AbCellera’s poster presentation describes the expansion, further characterization, and va
Nov 08, 2022 04:05 pm ET
AbCellera Reports Q3 2022 Business Results
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the third quarter of 2022. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
Nov 04, 2022 04:05 pm ET
AbCellera to Present at Upcoming Investor Conferences in November
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences:
Nov 02, 2022 09:00 am ET
AbCellera’s First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development
AbCellera (Nasdaq: ABCL) announced today that Regeneron has elected to exercise its right to advance a therapeutic antibody candidate, discovered in partnership with AbCellera as part of a multi-target collaboration between the companies, into further preclinical development. The partnership, which commenced in March 2020 and allows for four discovery prog
Oct 11, 2022 04:05 pm ET
AbCellera to Report Third Quarter 2022 Financial Results on November 8, 2022
AbCellera (Nasdaq: ABCL) will announce its third quarter 2022 financial results on Tuesday, November 8, 2022, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
Oct 05, 2022 08:00 am ET
AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022
AbCellera (Nasdaq: ABCL) today announced a presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held virtually and at the Boston Convention & Exhibition Center from November 8 to 12, 2022.
Sep 21, 2022 08:00 am ET
AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic
AbCellera (Nasdaq: ABCL) today announced it has launched the second phase of its global headquarters expansion by breaking ground on its new facility in Vancouver, Canada. The 380,000-square-foot tech campus will include state-of-the-art lab and office spaces to support AbCellera’s capabilities in bringing new antibody-based medicines from target to the clini
Aug 09, 2022 04:05 pm ET
AbCellera Reports Q2 2022 Business Results
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the second quarter of 2022. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
Aug 03, 2022 07:00 am ET
AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients
AbCellera (Nasdaq: ABCL) and Atlas Venture announced a multi-target partnership to discover therapeutic antibod
Jul 27, 2022 07:00 am ET
Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies
AbCellera (Nasdaq: ABCL) and Versant Ventures today announced a multi-year collaboration to discover
Jul 12, 2022 04:05 pm ET
AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022
AbCellera (Nasdaq: ABCL) will announce its second quarter 2022 financial results on Tuesday, August 9, 2022, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
Jun 29, 2022 11:04 am ET
Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options
AbCellera (Nasdaq: ABCL) today announced that Eli Lilly and Company (Lilly) has entered into a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab, the second antibody developed through AbCellera’s collaboration with Lilly, for approximately $275 million. The existing U.S. government supply of bebtelovima
May 10, 2022 04:05 pm ET
AbCellera Reports Q1 2022 Business Results
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the first quarter of 2022. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
May 03, 2022 09:00 am ET
AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration
AbCellera (Nasdaq: ABCL) and Empirico Inc. (“Empirico”) announced today that they have expanded their strategic multi-target discovery collaboration, which leverages Empirico’s Precision Insights PlatformTM to discover genetically validated drug targets and AbCellera’s technology to identify lead candidate antibodies against those targets. Following the rapid progress of their first collaborative program, which identified a lead candidate against an undisclosed G protein-coupled receptor (GPCR) target in less than 12 months, the companies have expanded their partnershi
Apr 26, 2022 04:05 pm ET
AbCellera to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on Monday, May 2, 2022, in Toronto, Canada at 6:30 a.m. Pacific Time (9:30 a.m. Eastern Time).
Apr 12, 2022 04:05 pm ET
AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022
AbCellera (Nasdaq: ABCL) will announce its first quarter 2022 financial results on Tuesday, May 10, 2022, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
Apr 08, 2022 01:05 pm ET
AbCellera Presents Data on T Cell Engager Platform at AACR 2022
AbCellera (Nasdaq: ABCL), a technology company focused on next-generation antibody discovery, today announced the release of data on its new T cell engager platform at the American Association for Cancer Research (AACR) 2022 Annual Meeting. AbCellera’s poster presentation describes the discovery, characterization, and validation of a diverse panel of CD3-bind
Feb 24, 2022 04:05 pm ET
AbCellera Reports Full Year 2021 Business Results
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for full year 2021. All financial information in this press release is reported in U.S. dollars.
Feb 23, 2022 04:05 pm ET
AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will participate in a panel during the Truist Securities AI Symposium – Biotech & Tools. The panel is titled, “Integrated Platforms for AI-based Drug Discovery,” and will take place virtually on Tuesday, March 1, 2022, at 8:20 a.m. Pacific Time.
Feb 11, 2022 04:05 pm ET
AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022, at 12:40 p.m. Pacific Time.
Feb 11, 2022 03:37 pm ET
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19
AbCellera (Nasdaq: ABCL) today announced that bebtelovimab (LY-CoV1404), the second antibody developed through AbCellera’s collaboration with Eli Lilly and Company (Lilly), has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Bebtelovimab is authorized for the treatment of mild-to-moderate COVID-19 in adults and ped
Feb 10, 2022 07:40 pm ET
Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments
AbCellera (Nasdaq: ABCL) today announced Eli Lilly and Company (Lilly) has entered into a purchase agreement with the U.S. government to supply up to 600,000 doses, for at least $720 million, of investigational drug bebtelovimab (LY-CoV1404), the second antibody developed through AbCellera’s collaboration with Lilly. The U.S. government will accept the doses
Jan 27, 2022 04:05 pm ET
AbCellera to Report Full Year 2021 Financial Results on February 24, 2022
AbCellera (Nasdaq: ABCL) announced today that it will report full year 2021 financial results after market close on Thursday, February 24, 2022 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
Dec 07, 2021 09:00 am ET
AbCellera Announces Changes to Its Board of Directors
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced changes to its Board of Directors with the appointment of Andrew W. Lo, Ph.D., as an independent director and the resignation of John Hamer, Ph.D. Changes are effective immediately.
Dec 03, 2021 04:05 pm ET
AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12
AbCellera (Nasdaq: ABCL) today announced the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab administered together to include pediatric patients under the age of 12, including neonates (infants
Dec 02, 2021 09:00 am ET
AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, announced today the appointment of Neil Aubuchon as Chief Commercial Officer (CCO). Mr. Aubuchon brings over 20 years of experience in strategic planning, operations, and leadership for global biopharmaceutical companies, including te
Nov 09, 2021 04:05 pm ET
AbCellera Reports Q3 2021 Business Results
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the third quarter of 2021. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
Nov 04, 2021 04:05 pm ET
AbCellera Announces Virtual Presentations at Investor Conferences in November
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following virtual investor conferences:
Nov 02, 2021 04:04 pm ET
Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19
AbCellera (Nasdaq: ABCL) today announced an additional purchase by the U.S. government from Eli Lilly and Company (Lilly) for bamlanivimab with etesevimab for administration together. This neutralizing antibody therapy is authorized for emergency use for the treatment of mild to moderate COVID-19 or for post-exposure prophylaxis of COVID-19 in certain ind
Oct 14, 2021 04:05 pm ET
AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021
AbCellera (Nasdaq: ABCL) will announce its third quarter 2021 financial results on Tuesday, November 9, 2021, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
Sep 22, 2021 06:00 pm ET
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, “Everest”) announced t
Sep 21, 2021 01:55 pm ET
Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19
AbCellera (Nasdaq: ABCL) today announced the European Commission (EC) and Eli Lilly and Company (Lilly) have entered into a Joint Procurement Agreement to supply up to 220,000 doses of bamlanivimab together with etesevimab to treat confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at in
Sep 17, 2021 08:30 am ET
Thinking about buying stock in Corvus Pharmaceuticals, AbCellera Biologics, Rekor Systems, SmileDirectClub, or Arcus Biosciences?
NEW YORK, Sept. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRVS, ABCL, REKR, SDC, and RCUS.
Sep 16, 2021 04:15 pm ET
Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
AbCellera (Nasdaq: ABCL) today announced the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg administered with etesevimab (LY-CoV016) 1400 mg to include post-exposure prophylaxis (PEP) to prevent SARS-CoV-2 infection or symptomatic COVID-19. The neutralizing antibodies, which we
Sep 15, 2021 09:00 am ET
AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines
AbCellera (Nasdaq: ABCL) announced today that it entered into a multi-year, multi-target research collaboration and license agreement with Moderna to leverage AbCellera’s AI-powered technology to search and analyze natural immune responses to identify therapeutic antibodies against up to six targets selected by Moderna.
Sep 13, 2021 09:00 am ET
AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced it has acquired TetraGenetics, Inc. (TetraGenetics), a biotechnology company with a proprietary platform for generating recombinant human ion channels and other transmembrane proteins, in an all-cash transaction that includes an upfront payment, the potential for payments based on the achievement of technical milestones, and additional development and commercial milestone payments related to successfully developed therapeutics.
Sep 10, 2021 04:17 pm ET
AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present virtually at the BofA Securities  – Tech Solutions for Drug Discovery Conference on Monday, September 20, 2021, at 9:00 a.m. Pacific Time.
Sep 07, 2021 08:30 am ET
Thinking about buying stock in Adaptimmune Therapeutics, Ziopharm Oncology, Uniqure NV, GlycoMimetics, or AbCellera Biologics?
NEW YORK, Sept. 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADAP, ZIOP, QURE, GLYC, and ABCL.
Aug 12, 2021 04:05 pm ET
AbCellera Reports Q2 2021 Business Results
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the second quarter of 2021. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
Aug 04, 2021 07:00 am ET
EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines
EQRx, a company committed to developing and delivering important new medicines at radically lower prices, and AbCellera (Nasdaq: ABC
Aug 04, 2021 07:00 am ET
EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines
EQRx, a company committed to developing and delivering important new medicines at radically lower prices, and AbCellera (Nasdaq: ABC
Aug 03, 2021 06:00 am ET
Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer
Tachyon Therapeutics, Inc. (Tachyon), a research and development focused biotechnology company, and AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced a collaboration to facilitate the discovery and development of a therapeutic antibody targeting LEFTY1, a member of the transforming growth factor β (TGF-β) superfamily and validated extracellular drug target expressed in advanced cancers. Under the terms of the agreement, AbCellera is eligible to receive milestone payments and royalties on products that are
Jul 22, 2021 04:05 pm ET
AbCellera to Report Second Quarter 2021 Financial Results on August 12, 2021
AbCellera (Nasdaq: ABCL) will announce its second quarter 2021 financial results on Thursday, August 12, 2021 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
Jul 13, 2021 09:00 am ET
AbCellera Appoints Neil Berkley as Chief Business Officer
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, announced today that Neil Berkley has been appointed as Chief Business Officer (CBO). Mr. Berkley’s role will include leading the strategy and continued growth of AbCellera’s partnership business, which currently includes a diverse po
Jun 22, 2021 09:00 am ET
AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada
AbCellera (Nasdaq: ABCL) today announced it has secured a site in Vancouver for the construction of a Good Manufacturing Practices (GMP) manufacturing facility for the production of therapeutic antibodies, which will be the first of its kind in Canada. The 130,000-square-foot facility will expand AbCellera’s capabilities in bringing new antibody therapies to clinical trials, supporting Canada’s efforts to respond quickly and effectively to future pandemics and providing AbCellera’s partners with a full solution for accelerating their programs from a drug target to the submission of an Investig
Jun 10, 2021 05:11 pm ET
AbCellera Announces Secondary Private Sale of 11.9 Million Common Shares
AbCellera (Nasdaq: ABCL) today announced that certain entities owned and/or controlled, directly or indirectly, by Carl Hansen, Ph.D., Cofounder, Chief Executive Officer, and President of AbCellera, and other senior leaders (collectively, the “Selling Shareholders”), have entered into separate share purchase agreements with experienced institutional investors
May 14, 2021 08:48 pm ET
CORRECTING and REPLACING AbCellera Reports Q1 2021 Business Results
In the release dated May 13, 2021, the “Program starts, cumulative” figure for the period ended March 31, 2021 in both the Key Business Metrics table and the following paragraph should read 54 instead of 52. The resulting percent change from the prior period (“Change %) in the table should read 15% instead of 11%.
May 13, 2021 04:05 pm ET
AbCellera Reports Q1 2021 Business Results
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the first quarter of 2021.
May 11, 2021 04:05 pm ET
AbCellera to Present Virtually at Berenberg Conference on May 18, 2021
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present virtually at the Berenberg Conference USA 2021 on Tuesday, May 18, 2021 at 11:00 a.m. Pacific Time.
May 06, 2021 09:00 am ET
AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy
AbCellera (Nasdaq: ABCL) and Angios GmbH (Angios) announced today that they have entered into a multi-year, multi-target collaboration to facilitate the discovery of monoclonal and bispecific antibodies for vascular diseases of the eye. AbCellera will use its full stack, AI-powered antibody discovery platform to generate panels of antibodies for up to three Angios-selected targets to address diabetic retinopathy.
May 04, 2021 06:30 am ET
New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials
AbCellera (Nasdaq: ABCL) today announced that a second antibody from its collaboration with Eli Lilly and Company (Lilly), LY-CoV1404, has entered
Apr 29, 2021 04:10 pm ET
AbCellera Breaks Ground on Global Headquarters in Vancouver and Expects to Hire Hundreds of Scientific and Tech Professionals
AbCellera (Nasdaq: ABCL), a technology company that has developed a centralized operating system for next-generation antibody discovery and development, today announced it has broken ground on an expanded global headquarters in its home city of Vancouver in anticipation of adding hundreds of employees to its current 250-person workforce over the next few years.
Apr 21, 2021 04:05 pm ET
AbCellera to Report First Quarter 2021 Financial Results on May 13, 2021
AbCellera (Nasdaq: ABCL) will announce its first-quarter 2021 financial results on Thursday, May 13, 2021 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
Apr 14, 2021 04:05 pm ET
AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration
AbCellera (Nasdaq: ABCL) and Empirico Inc. (“Empirico”) announced today that they have entered into a strateg
Apr 12, 2021 04:05 pm ET
AbCellera to Present Virtually at Upcoming Investor Conferences
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following virtual investor conferences:
Apr 05, 2021 02:00 pm ET
Published Peer-Reviewed Data Demonstrate Bamlanivimab’s High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19
AbCellera (Nasdaq: ABCL) and collaborators today announced the publication of research in Science Translational Medicine characterizing the high potency of bamlanivimab (LY-CoV555) to neutralize SARS-CoV-2 by uniquely binding both the up and down confirmations of the spike receptor-b
Apr 01, 2021 09:00 am ET
AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration
AbCellera (Nasdaq: ABCL) today announced agreements to expand its collaboration with Gilead Sciences, Inc. (Gilead) including a multi-year, multi-target antibody discovery collaboration and access to AbCellera’s humanized mouse technology, the Trianni Mouse®. Under the financial terms of the agreements, AbCellera will receive an upfront paym
Mar 29, 2021 04:05 pm ET
AbCellera Reports Full Year 2020 Business Results
AbCellera (NASDAQ: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the full year 2020 with the following highlights.
Mar 10, 2021 11:21 am ET
AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19
AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), and etesevimab 1400 mg (LY-CoV16) together reduced COVID-19-related hospitalizations and deaths by 87% in high-risk patients recently diagnosed with COVID-19. These results mark the secon
Mar 05, 2021 03:30 pm ET
EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients
AbCellera (Nasdaq: ABCL) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for bamlanivimab alone and bamlanivimab administered together with etesevimab. The opinion advises bamlanivimab alone and bamlanivimab administered together with etesevimab can be used for the treatment of confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at high risk of progressing to severe COVID-19. The CHMP recommendation provides a harmonized,
Feb 17, 2021 04:05 pm ET
AbCellera to Present at the SVB Leerink Global Healthcare Conference
AbCellera (NASDAQ: ABCL) will present at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 1:20 p.m. Pacific Time.
Feb 11, 2021 04:05 pm ET
AbCellera Appoints Ester Falconer, Ph.D., as Chief Technology Officer
AbCellera (Nasdaq: ABCL) announced today that Ester Falconer, Ph.D., has been appointed as Chief Technology Officer (CTO), effective January 28, 2021.
Feb 09, 2021 08:26 pm ET
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19
“The data show that bamlanivimab alone and bamlanivimab and etesevimab together are effective at reducing hospitalizations in high-risk COVID-19 patients, with consistent and similar efficacy across studies,” said Carl Hansen, Ph.D., CEO and President of AbCellera. “With this EUA for bamlanivimab and etesevimab together, there are more treatment options for patients at high risk for hospitalization and another layer of protection against the emergence of new viral variants.”
Feb 03, 2021 04:05 pm ET
AbCellera Announces Date of Fourth Quarter 2020 Financial Results Conference Call
AbCellera (Nasdaq: ABCL) will announce its fourth-quarter and full-year 2020 financial results on Monday, March 29, 2021 after the U.S. stock markets close and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
Jan 27, 2021 07:22 am ET
AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19
AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), will be evaluated together with VIR-7831, an antibody developed by Vir Biotechnology, Inc. and GlaxoSmithKline, as a potential COVID-19 therapy in low-risk patients with mild to moderate COVID-19
Jan 26, 2021 07:09 am ET
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70%
AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555) 2800 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), and etesevimab 2800 mg (LY-CoV16) together significantly reduced COVID-19 related hospitalizations and deaths (collectively, “events”) in more than 1,000 high-risk patients recently diagnosed with COVID-19.
Jan 21, 2021 08:27 am ET
AbCellera-Discovered Antibody Prevented COVID-19 in Nursing Homes and Reduced Risks by up to 80% for Residents
AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities. Lilly’s Phase 3 BLAZE-2 COVID-19 prevention trial was conducted in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the COVID-19 Prevention Network (CoVPN).
Jan 19, 2021 04:41 pm ET
AbCellera Granted U.S. Patent Covering its Trianni Mouse® Technology
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced it has expanded its intellectual property (IP) portfolio to include its Trianni Mouse® technology. AbCellera uses the transgenic animal technology to generate fully human monoclonal antibodies for its drug di
Jan 05, 2021 08:30 am ET
2020 Canadian IPO mixed results - number (77) down, amount ($5.55B) up driven by PE-backed IPOs
TORONTO, Jan. 5, 2021 /CNW/ - While the US initial public offering (IPO) and special purpose acquisition corporation (SPAC) market experienced an unprecedent boom in 2020, Canadian IPO market continued to struggle with mixed results.
Dec 21, 2020 09:00 am ET
AbCellera-Discovered Neutralizing Antibody for COVID-19 Enters New Pragmatic Study in New Mexico
AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody developed through AbCellera’s collaboration with Eli Lilly and Company (Lilly), will be evaluated in a new pragmatic study in high-risk patients with COVID-19. Lilly’s trial, in collaboration with the state of New Mexico and major local institutions, will collect data on the effectiveness and safety of bamlanivimab in a real-world setting that includes a diverse population and spans both rural and urban environments. As part of this study, Lilly will employ its unique mobile research units used successfull
Dec 15, 2020 09:03 pm ET
AbCellera Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
AbCellera Biologics Inc. (“AbCellera”) (Nasdaq: ABCL), a technology company that aims to become the centralized operating system for next-generation antibody discovery, today announced the closing of its initial public offering of 27,772,500 common shares at a price to the public of $20.00 per share, which includes the exercise in full of the underwriters’ option to purchase 3,622,500 additional common shares. All of the common shares were offered by AbCellera. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were ap
Dec 10, 2020 10:47 pm ET
AbCellera Announces Pricing of Initial Public Offering
AbCellera Biologics Inc. (“AbCellera”), a technology company that aims to become the centralized operating system for next-generation antibody discovery, today announced the pricing of its initial public offering of 24,150,000 common shares at a price to the public of $20.00 per share. All of the common shares are being offered by AbCellera. In addition, AbCellera has granted the underwriters a 30-day option to purchase up to 3,622,500 additional common shares at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on The Nasd

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.